Prediction: This Stock Could Double By 2031

Exelixis reported Q1 revenue up 10% year over year to $610.8 million and guided fiscal 2026 revenue to $2.58 billion at the midpoint, about 11% above the prior year. Cabometyx should keep driving growth through early 2030 before generic competition, while zanzalintinib is awaiting approval in metastatic colorectal cancer and could eventually reach $5 billion in peak sales. The article is bullish on the company’s medium-term pipeline, but the piece is largely long-term stock commentary rather than near-term price-moving news.

Analysis

EXEL remains in a classic late-cycle single-franchise transition, but the key market implication is that the stock’s multiple should be driven less by peak current revenue and more by the probability-weighted durability of the next asset. That creates a window where the equity can rerate before the eventual patent cliff is visible in earnings, because investors typically underprice the optionality of a second asset until phase-3 and early label expansion data are de-risked.

The important second-order effect is competitive positioning in RCC and adjacent oncology niches: if the next product gains traction, it can preserve commercial leverage with the same specialty sales infrastructure and payer relationships, limiting SG&A inflation versus a true new-launch story. More broadly, a credible successor asset reduces the need for dilutive M&A, which is often the hidden overhang on mid-cap biotechs when lead products age.

The main tail risk is not just binary regulatory failure, but a sequence risk: a slow launch, narrow initial label, or weaker-than-expected RCC readouts would force the market to look through a 12-24 month trough in growth before the pipeline can backfill. In that scenario, the stock likely de-rates well ahead of any actual generic erosion, because the market will discount the transition gap rather than the eventual expiration itself.

Consensus seems to be treating this as a straightforward “own until the next drug arrives” story, but the better framing is that EXEL is a timing trade on data cadence and label breadth. If zanzalintinib gets an approvable profile plus convincing expansion data in the next two readouts, the stock can compound on duration extension rather than on peak-sales headlines alone; if not, the market will likely compress the multiple long before 2030.

Key Decisions for Investors

• Initiate a tactical long EXEL into the next RCC data window, with a 3-6 month horizon; upside is a multiple expansion on pipeline de-risking, while the stop is a sharp derating if readouts fail to show clear label-expansion potential.
• For existing longs, monetize part of the position after binary catalysts and re-enter on pullbacks; the risk/reward is best when implied event premium is elevated but before commercial launch expectations are fully embedded.
• Pair trade: long EXEL / short a basket of weaker mid-cap oncology names with thinner late-stage pipelines; the relative thesis is better transition visibility and less financing risk if zanzalintinib continues to validate.
• If options are liquid, consider a call spread rather than outright calls around catalyst dates; this captures upside from a positive approval/data sequence while limiting decay if the market has already priced in too much optimism.
• Avoid adding aggressively on approval alone without read-through on RCC and additional indications; the highest-quality entry is after the market confirms that the asset can become a multi-indication franchise, not just a one-label replacement.